本报记者 王僖 2月10日晚间，东阿阿胶股份有限公司（以下简称"东阿阿胶"）发布公告称，公司拟投资14.85亿元自有资金建设健康消费 品产业园项目，其中固定资产投资14.21亿元，铺底流动资金0.64亿元。该举措标志着东阿阿胶在转型升级中迈出关键一步，进 一步彰显其深耕大健康产业的战略决心。 公告显示，该项目将打造集药食同源食品、保健品、功能性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵 化中心、电商分拣及药品成品仓储于一体的综合性基地。 养生年轻化 滋补类中药行业正迎来黄金发展期，年轻一代正迅速成为滋补类中药的消费主力。《天猫保健滋补行业消费场景与人群洞 察》显示，从2020年到2024年，保健滋补行业人均消费提升31%，成交人数提升34%，这一趋势体现了健康养生市场的年轻化 转变。 前述东阿阿胶负责人表示，东阿阿胶健康消费品产业园项目正是看准了银发经济这一历史性机遇，项目建成后将为老年人 提供更多高品质、个性化的健康消费品。 夯实发展基础 东阿阿胶在滋补产业领域拥有深厚的全产业链布局，为健康消费品产业园项目奠定了坚实基础。据前述东阿阿胶负责人介 绍，目前该公司已突破阿胶口服含化技术，研发出阿胶速 ...

Core Insights - Dong'e Ejiao reported a revenue of 4.766 billion yuan and a net profit of 1.274 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 10.10% and 10.58% respectively, after excluding retrospective adjustments [1][4] - The company has achieved five consecutive years of high growth since 2020, positioning itself as a benchmark in the traditional Chinese medicine industry [2][3] - The company is implementing the "1238" development strategy under the leadership of Chairman Cheng Jie, focusing on expanding into the health consumption market with new products [2][9] Financial Performance - In the first three quarters of 2025, after retrospective adjustments, revenue growth was 4.41% and net profit growth was 10.53% [4] - Despite the technical decline in revenue growth due to adjustments, the net profit growth remained in double digits, indicating strong operational quality [4] - The company completed a share acquisition in July 2025, which affected financial metrics due to the consolidation of financial statements [3][4] Market Position and Strategy - Dong'e Ejiao is a leading brand in the Chinese herbal medicine sector, with a market share exceeding 70% in the ejiao block category and over 25% in the compound ejiao syrup category [9][10] - The company is diversifying its product offerings, including health products targeting men's health, and has launched several new products in recent years [2][10] - The "1238" strategy emphasizes dual-driven development in pharmaceuticals and health consumer goods, aiming to create a second growth curve [9][10] Leadership and Collaboration - Chairman Cheng Jie has been appointed as the executive director and president of China Resources Pharmaceutical Group, enhancing collaboration between Dong'e Ejiao and the state-owned enterprise [6][7] - Cheng's leadership has contributed to the company's robust growth, with a compound annual growth rate of 21.28% in revenue and 41.29% in net profit over the past three years [7][8] - The integration of resources and expertise from the parent group is expected to support Dong'e Ejiao's sustainable development [8][9] Innovation and Product Development - The company is focusing on innovation in product development, collaborating with universities to establish a scientific evidence system for new product development [11] - New product launches include red ginseng and other health supplements, aimed at enhancing market presence and addressing consumer needs [10][11] - Dong'e Ejiao's strategy includes balancing traditional strengths with innovative breakthroughs to navigate market challenges [11]

Group 1: Future Business Strategy - Dong-E E-Jiao will adhere to the "1238" strategy, focusing on the integration of the gelatin industry chain and enhancing its core business [1] - The company aims to improve digital capabilities and drive high-quality growth, aspiring to become a trusted leader in health supplements [1] Group 2: Investment and Acquisition Plans - Investment and acquisitions are key components of the "1238" strategy, with a focus on potential targets in the health supplement sector [1] - The company is implementing a "dual-wheel drive" strategy for investment direction, particularly in pharmaceuticals and health consumer products [2] Group 3: Raw Material Supply Assurance - The company emphasizes the sustainable supply of donkey hide, focusing on both domestic and international markets [3] - Efforts include establishing a supply network and promoting policy guidance in key countries to ensure a stable supply chain [3] Group 4: New Product Development - The "Zhuangben" brand will focus on upstream material acquisition and introduce innovative products to the market [4] - The company plans to enhance brand recognition for "Ejiao Dates" and develop a variety of health snack products [4] - A new category for "Ejiao Bird's Nest" will be created, with a focus on brand optimization and product efficacy verification [4] Group 5: Profit Distribution and Dividends - Since its listing in 1996, the company has distributed dividends 26 times, totaling 8.469 billion yuan, with an average payout ratio of 65.75% [6] - For 2024, the company plans to distribute 818 million yuan, with a payout ratio of 99.87% [6] Group 6: Revenue Projections - In 2024, Dong-E E-Jiao block products are expected to account for approximately 45% of total revenue, while compound Ejiao syrup is projected to contribute nearly 35% [6] Group 7: Brand Development Initiatives - The "Royal Weichang 1619" brand aims to establish itself as a leading men's health brand, focusing on product and category expansion [7] - The "Peach Blossom Princess Ejiao Cake" brand will undergo a comprehensive brand renewal to capture the mainstream beauty market [7] Group 8: Financial Performance Insights - The company experienced a decline in cash flow and an increase in accounts receivable due to strategic credit management and increased procurement of raw materials [8]